evacetrapib + atorvastatin

LY2484595 (evacetrapib) + atorvastatin is an experimental oral fixed-dose combination of **evacetrapib**, a selective and potent cholesteryl ester transfer protein (CETP) inhibitor, with **atorvastatin**, an established HMG-CoA reductase inhibitor (statin). Evacetrapib inhibits CETP, leading to increases in high-density lipoprotein cholesterol (HDL-C) and reductions in low-density lipoprotein cholesterol (LDL-C)[3][1]. Atorvastatin lowers LDL-C by inhibiting cholesterol synthesis in the liver. The combination was developed to maximize lipid management in patients with hypercholesterolemia or low HDL-C. Clinical studies tested the combination for additive effects on HDL-C and LDL-C, pharmacodynamics, pharmacokinetics, and safety in comparison to monotherapy in lipid metabolism disorders[1].

Other names

LY2484595 + atorvastatin